Earnings summaries and quarterly performance for Kyverna Therapeutics.
Executive leadership at Kyverna Therapeutics.
Board of directors at Kyverna Therapeutics.
Research analysts who have asked questions during Kyverna Therapeutics earnings calls.
BC
Brad Canino
Stifel Financial Corp.
2 questions for KYTX
Also covers: BPMC, SMMT
Eric Joseph
JPMorgan Chase & Co.
2 questions for KYTX
Also covers: BEAM, BLUE, ENTA +9 more
Jeff Jones
Oppenheimer & Co. Inc.
2 questions for KYTX
Also covers: ABEO, CLRB, CMMB +8 more
KP
Kalpit Patel
B. Riley Securities
2 questions for KYTX
Also covers: DERM, FBRX, GERN +4 more
KS
Kelly Shee
Jefferies Financial Group Inc.
2 questions for KYTX
Michael Schmidt
Guggenheim Securities
2 questions for KYTX
Also covers: ADAP, ADCT, ARVN +19 more
AS
Alex Sanagathon
Tuist Securities
1 question for KYTX
Andy Chen
Wolfe Research, LLC
1 question for KYTX
Also covers: ARGX, CRNX, IMVT +7 more
CS
Chris Shibutani
Goldman Sachs Group, Inc.
1 question for KYTX
Also covers: ABBV, ALKS, BMY +11 more
C
Chuka
Wolf Research
1 question for KYTX
EM
Ellie Merle
UBS Group AG
1 question for KYTX
Also covers: ALNY, ALT, ARVN +12 more
FK
Faisal Khashid
Leary Partners
1 question for KYTX
Also covers: RYTM
G
Gospel
Morgan Stanley
1 question for KYTX
KD
Kripa Devarakonda
Truist Securities
1 question for KYTX
Also covers: ABCL, ARVN, BMY +5 more
MB
Mark Brown
TD Cowen
1 question for KYTX
MF
Mark Fram
TD Cohen
1 question for KYTX
VP
Vikram Paroth
Morgan Stanley
1 question for KYTX
Recent press releases and 8-K filings for KYTX.
Kyverna Therapeutics Appoints New Chief Technology Officer and Amends Equity Plan
KYTX
Management Change
Executive Compensation
Hiring
- Kyverna Therapeutics, Inc. announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026, succeeding Karen Walker who is retiring.
- Mr. Pujols brings over 30 years of technical operations expertise, including commercial manufacturing for CAR T-cell therapies, which is expected to be instrumental as Kyverna transitions to a commercial-stage company and prepares for the potential launch of miv-cel.
- In connection with his appointment, Mr. Pujols will receive an option to purchase 300,000 shares of common stock, vesting over four years.
- The company also amended its 2024 Inducement Equity Incentive Plan on January 29, 2026, increasing the maximum number of shares available for grant by 1,000,000 to an aggregate of 5,000,000 shares.
4 days ago
Kyverna Reports Transformative 2025 Progress and Outlines 2026 Milestones
KYTX
Product Launch
New Projects/Investments
Guidance Update
- Kyverna (KYTX) reported a transformative 2025, marked by transformational clinical data in Stiff Person Syndrome (SPS) and Myasthenia Gravis (MG), establishing a clear regulatory pathway, and advancing commercialization plans.
- The company concluded 2025 with $279 million in cash, providing a cash runway well into 2028, which fully funds the Biologics License Application (BLA) filing and commercial launch for SPS, as well as the Myasthenia Gravis Phase 3 trial.
- For 2026, key catalysts include the BLA filing for Stiff Person Syndrome in the first half of the year and preparations for its commercial launch, alongside maturing data from the Myasthenia Gravis Phase 2 trial and continued enrollment in its Phase 3 program.
- Kyverna is also developing KYV-102, a second-generation platform designed to simplify patient access, accelerate manufacturing, and reduce costs, with its Investigational New Drug (IND) application already filed and accepted by the FDA.
Jan 14, 2026, 5:45 PM
Kyverna Therapeutics Details Transformative 2025 and Outlines 2026 Milestones
KYTX
Product Launch
New Projects/Investments
Guidance Update
- Kyverna Therapeutics reported a transformative 2025, driven by transformational clinical data for Mivcel in Stiff Person Syndrome (SPS) and Myasthenia Gravis (MG).
- The company is on track to file its first Biologics License Application (BLA) for SPS in the first half of 2026, having established a clear regulatory pathway.
- Kyverna ended 2025 with $279 million in cash, providing a runway well into 2028 and fully funding key initiatives including the SPS BLA filing, commercial launch, and MG Phase 3 trial.
- The Investigational New Drug (IND) application for its second-generation platform, KYV-102, was filed and accepted, aiming to simplify CAR-T access, speed manufacturing, and reduce costs.
Jan 14, 2026, 5:45 PM
Kyverna Therapeutics Reports Transformative 2025 and Outlines 2026 Milestones
KYTX
Guidance Update
New Projects/Investments
Product Launch
- Kyverna Therapeutics achieved a transformative 2025, reporting transformational clinical data for its CAR T therapy, Mivcel, in Stiff Person Syndrome (SPS) and Myasthenia Gravis (MG).
- The company is on track to file its first Biologics License Application (BLA) for Stiff Person Syndrome in the first half of 2026, having established a clear regulatory pathway for both SPS and MG.
- Kyverna ended 2025 with $279 million in cash, providing a cash runway well into 2028 and fully funding the SPS BLA filing, commercial launch, and Myasthenia Gravis Phase III trial.
- Leveraging a first-mover advantage in autoimmune CAR T, Kyverna is preparing for the commercial launch of Mivcel for SPS, targeting 2,000-2,500 refractory patients and planning to onboard approximately 10 authorized treatment centers.
- An Investigational New Drug (IND) application was filed and accepted for KYV-102, a second-generation platform aimed at simplifying patient access, speeding up manufacturing, and reducing cost of goods.
Jan 14, 2026, 5:45 PM
Kyverna Therapeutics Provides Update on Financial Position, Miv-cel Clinical Progress, and Commercialization Plans
KYTX
New Projects/Investments
Guidance Update
Product Launch
- Kyverna Therapeutics reported a cash balance of $279 million as of December 31, 2025, and projects a cash runway into 2028, expected to fund key milestones including the SPS BLA filing, commercial launch, and Phase 3 gMG trial.
- The company plans to file a Biologics License Application (BLA) for Miv-cel in Stiff Person Syndrome (SPS) in 1H 2026, following positive registrational trial results, positioning it as a first-to-market therapy for an immediately addressable market of ~2.0 to 2.5 thousand patients.
- Interim Phase 2 results for Miv-cel in generalized Myasthenia Gravis (gMG) demonstrated 100% clinically meaningful response, with the Phase 3 registrational trial actively enrolling.
Jan 14, 2026, 5:45 PM
Kyverna Therapeutics Announces Financial Update, Strategic Milestones, and Board Appointment
KYTX
Guidance Update
Board Change
New Projects/Investments
- Kyverna Therapeutics completed a follow-on offering in December 2025, raising approximately $105 million in gross proceeds, which is expected to extend its cash runway into 2028.
- As of December 31, 2025, the company reported estimated, preliminary, and unaudited cash, cash equivalents, and marketable securities of approximately $279 million.
- The company plans to submit a Biologics License Application (BLA) for miv-cel in stiff person syndrome (SPS) in the first half of 2026 and enrolled the first patient in its registrational Phase 3 trial for generalized myasthenia gravis (gMG) in December 2025.
- Christi Shaw was appointed Executive Chairperson of the Board, effective January 12, 2026, with an initial annual salary of $400,000.
Jan 12, 2026, 1:00 PM
Kyverna Provides Update on Miv-cel Programs for SPS and gMG, Reports Strong Financial Position
KYTX
Product Launch
New Projects/Investments
Guidance Update
- Kyverna (KYTX) is progressing its Miv-cel (CD19 CAR T) program, with a Biologics License Application (BLA) filing for Stiff Person Syndrome (SPS) anticipated in 1H 2026 and full pivotal data for generalized Myasthenia Gravis (gMG) expected in 1H 2026, targeting gMG launch readiness by year-end 2026.
- Miv-cel has demonstrated statistically significant benefits in the SPS registrational trial and transformative clinical efficacy in gMG, achieving 100% clinically meaningful response in interim Phase 2 results.
- The company maintains a strong financial position with a cash balance of $279 million as of December 31, 2025, providing a cash runway into 2028 to fund key milestones including the SPS BLA filing, commercial launch, and the Phase 3 gMG trial.
Jan 12, 2026, 12:00 PM
Kyverna Therapeutics Announces Pricing of Public Offering of Common Stock
KYTX
- Kyverna Therapeutics, Inc. (KYTX) announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of $7.50 per share.
- The offering is expected to generate approximately $100 million in gross proceeds for Kyverna, before deducting underwriting discounts and commissions and offering expenses.
- Kyverna has granted the underwriters a 30-day option to purchase up to an additional 1,999,999 shares of common stock.
- The net proceeds from the offering are intended for general corporate purposes, which may include funding research and development, capital expenditures, working capital, and general and administrative expenses.
Dec 18, 2025, 2:50 AM
Kyverna Therapeutics prices $100 million public offering of common stock
KYTX
- Kyverna Therapeutics announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of $7.50 per share.
- The offering is expected to generate approximately $100 million in gross proceeds for Kyverna.
- All shares in the offering are being sold by Kyverna, and the offering is anticipated to close on or about December 18, 2025.
- Kyverna has granted the underwriters a 30-day option to purchase up to an additional 1,999,999 shares of its common stock.
Dec 17, 2025, 2:24 PM
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
KYTX
- Kyverna Therapeutics has commenced an underwritten public offering of $100,000,000 of its common stock.
- The company intends to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of shares of common stock.
- All shares in the proposed offering will be sold by Kyverna, with J.P. Morgan, Leerink Partners, Morgan Stanley, and Wells Fargo Securities acting as joint book-running managers.
- The proposed offering is subject to market and other conditions, and there is no assurance as to whether or when it may be completed or its actual size or terms.
Dec 15, 2025, 9:01 PM
Quarterly earnings call transcripts for Kyverna Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more